Business
Additional Listing
Additional Listing.
About this update from Aura Renewable Acquisitions Plc
[{"type":"text","content":"\n Ardana PLC\n03 May 2006\n\n3 May 2006\n\n\n BLOCK LISTING\n\n\nEdinburgh, UK, 03 May 2006; Ardana plc (LSE:ARA) the emerging pharmaceutical\ncompany focused on improving human reproductive health, today announces that\napplication has been made to the UK Listing Authority and the London Stock\nExchange for a block listing of 2,494,967 ordinary shares of 1 (one) pence each.\n The application is in respect of shares to be allotted pursuant to the\nexercise of options under the Ardana Bioscience Employees' share option scheme,\nArdana Ltd Employees' share option scheme and certain individual option\nagreements between Ardana plc and non-executive directors and non-employees.\n\n\n\nFor more information contact:\n\n\nArdana\nMaureen Lindsay Tel: + 44 (0) 131 226 8550\n\n\n\nAbout Ardana\n\nArdana plc is a pharmaceutical company focused on the discovery, development and\nmarketing of innovative products to improve human reproductive health, a $23.8\nbillion market.\n\n\n\nSince its foundation, Ardana has maintained a broad and balanced portfolio to\nmanage risk and actively pursues product and technology in-licensing and\nout-licensing to maintain a robust pipeline.\n\n\n\nArdana's four lead products are summarised below:\n\n\n\n• StriantTM SR, a testosterone replacement therapy for which Ardana has\n marketing rights in Europe, has already been launched by Ardana through its \n own sales force in the UK as a treatment for men with confirmed hypogonadism\n\n• Teverelix LA, in development for three initial indications: prostate cancer \n and benign prostatic hyperplasia (both indications are at the phase II \n stage), and endometriosis (currently in phase I)\n\n• Testo Cream, a transdermal testosterone delivery system in phase II for the \n treatment of male hypogonadism\n\n• Invicorp(R), an injectable combination drug treatment for erectile\n dysfunction, already approved in Denmark and for which Ardana has marketing \n and manufacturing rights in Europe. Launch is expected in H2 2006\n\n\n\nIn addition, Ardana has a strong portfolio of follow-on products in development.\nArdana completed its IPO on the London Stock Exchange in March 2005 raising\n£21 million.\n\nFor further information please see www.ardana.co.uk\n\n\n\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange...